SpeedScreen: The "missing link" between genomics and lead discovery.
Zehender
Hartmut
H
Novartis Institutes for Biomedical Research, Discovery Technologies/Basel Screening Operations, 4002 Basel, Switzerland. hartmut.zehender@pharma.novartis.com
Le Goff
Francois
F
Lehmann
Natalie
N
Filipuzzi
Ireos
I
Mayr
Lorenz M
LM
D002850:Chromatography, Gel / Q000379:methods; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D015195:Drug Design; D004867:Equipment Design; D023281:Genomics; D007854:Lead / Q000032:analysis* / Q000737:chemistry; D013058:Mass Spectrometry / Q000379:methods; D008962:Models, Theoretical; D011485:Protein Binding; D012680:Sensitivity and Specificity; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods; D013678:Technology, Pharmaceutical / Q000295:instrumentation
D007854:Lead